{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:07:06Z","timestamp":1785434826750,"version":"3.56.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019996","name":"The Medical Association of Thailand","doi-asserted-by":"crossref","award":["Dr Prasert Prasarttong-Osoth Research Grant"],"award-info":[{"award-number":["Dr Prasert Prasarttong-Osoth Research Grant"]}],"id":[{"id":"10.13039\/100019996","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Chronic inflammation has been described in people living with HIV (PLHIV) receiving antiretroviral therapy (ART) despite viral suppression. Inflammation associated non-communicable diseases, including atherosclerosis, are becoming recognized complication of HIV infection. We studied the effect of pitavastatin on atherosclerotic-associated inflammatory biomarkers in PLHIV receiving ART.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A randomized, double-blind, crossover study was conducted in HIV-infected persons with dyslipidemia and receiving atazanavir\/ritonavir (ATV\/r) to evaluate the effect of 2\u00a0mg\/day pitavastatin treatment versus placebo. High-sensitivity CRP (hs-CRP), cytokines, and cellular markers in PLHIV receiving 12\u00a0weeks of pitavastatin or placebo were investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 24 HIV-infected individuals with a median (interquartile range) age of 46 (41\u201354) years were recruited, and the median CD4 T cell count was 662 (559-827) cells\/mm<jats:sup>3<\/jats:sup>. The median duration of ATV\/r use was 36 (24\u201348) months. Significant change in levels of basic fibroblast growth factor (FGF) between pitavastatin treatment and placebo at week 12 from baseline was observed (27.1 vs. 20.5\u00a0pg\/mL; p=0.023). However, there were no significant changes from baseline of hs-CRP and other plasma cytokine levels at week 12 of pitavastatin or placebo. Regarding cellular markers, percentages of HLA-DR<jats:sup>+<\/jats:sup>CD38<jats:sup>-<\/jats:sup>CD4<jats:sup>+<\/jats:sup> T cells and PD1<jats:sup>+<\/jats:sup>CD4<jats:sup>+<\/jats:sup> T cells significantly decreased from baseline in PLHIV receiving pitavastatin for 12\u00a0weeks, as compared to placebo (\u2212\u00a00.27 vs. 0.02%; p=0.049 and \u2212\u00a00.23 vs. 0.23%; p=0.022, respectively).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Pitavastatin treatment increases basic FGF levels, and lowers HLA-DR<jats:sup>+<\/jats:sup>CD38<jats:sup>-<\/jats:sup>CD4<jats:sup>+<\/jats:sup> T cells, and PD1<jats:sup>+<\/jats:sup>CD4<jats:sup>+<\/jats:sup> T cells. Further study on the effects of pitavastatin on preventing cardiovascular diseases in PLHIV should be pursued.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12981-023-00506-2","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T09:02:44Z","timestamp":1677488564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study"],"prefix":"10.1186","volume":"20","author":[{"given":"Sirawat","family":"Srichatrapimuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artit","family":"Wongsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somnuek","family":"Sungkanuparph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasisopin","family":"Kiertiburanakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boonrat","family":"Tassaneetrithep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angsana","family":"Phuphuakrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,27]]},"reference":[{"issue":"51","key":"506_CR1","first-page":"83","volume":"119","author":"MM Lederman","year":"2013","unstructured":"Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol. 2013;119(51):83.","journal-title":"Adv Immunol"},{"issue":"1","key":"506_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/imr.12079","volume":"254","author":"M Paiardini","year":"2013","unstructured":"Paiardini M, Muller-Trutwin M. HIV-associated chronic immune activation. Immunol Rev. 2013;254(1):78\u2013101.","journal-title":"Immunol Rev."},{"issue":"2","key":"506_CR3","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.amjcard.2015.10.030","volume":"117","author":"MJ Feinstein","year":"2016","unstructured":"Feinstein MJ, Bahiru E, Achenbach C, Longenecker CT, Hsue P, So-Armah K, et al. Patterns of cardiovascular mortality for HIV-infected adults in the United States: 1999 to 2013. Am J Cardiol. 2016;117(2):214\u201320.","journal-title":"Am J Cardiol."},{"issue":"8","key":"506_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11908-018-0628-7","volume":"20","author":"M Mosepele","year":"2018","unstructured":"Mosepele M, Molefe-Baikai OJ, Grinspoon SK, Triant VA. Benefits and risks of statin therapy in the HIV-infected population. Curr Infect Dis Rep. 2018;20(8):20.","journal-title":"Curr Infect Dis Rep."},{"key":"506_CR5","unstructured":"Panel of Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. 2022. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv. Accessed 24 Jan 2023."},{"issue":"3","key":"506_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/QAD.0b013e32835b2ef1","volume":"27","author":"A Monforte","year":"2013","unstructured":"Monforte A, Reiss P, Ryom L, El-Sadr W, Dabis F, De Wit S, et al. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. AIDS. 2013;27(3):407\u201315.","journal-title":"AIDS"},{"issue":"6","key":"506_CR7","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1016\/S2352-3018(18)30043-2","volume":"5","author":"L Ryom","year":"2018","unstructured":"Ryom L, Lundgren JD, El-Sadr W, Reiss P, Kirk O, Law M, et al. Cardiovascular disease and use of contemporary protease inhibitors: the D:A: D international prospective multicohort study. Lancet HIV. 2018;5(6):e291\u2013300.","journal-title":"Lancet HIV"},{"issue":"3","key":"506_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1086\/649897","volume":"201","author":"SW Worm","year":"2010","unstructured":"Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201(3):318\u201330.","journal-title":"J Infect Dis"},{"issue":"7","key":"506_CR9","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/S2352-3018(22)00094-7","volume":"9","author":"B Neesgaard","year":"2022","unstructured":"Neesgaard B, Greenberg L, Miro JM, Grabmeier-Pfistershammer K, Wandeler G, Smith C, et al. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. Lancet HIV. 2022;9(7):e474\u201385.","journal-title":"Lancet HIV"},{"issue":"7","key":"506_CR10","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3851\/IMP1666","volume":"15","author":"J Ghosn","year":"2010","unstructured":"Ghosn J, Carosi G, Moreno S, Pokrovsky V, Lazzarin A, Pialoux G, et al. Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. Antivir Ther. 2010;15(7):993\u20131002.","journal-title":"Antivir Ther"},{"issue":"3","key":"506_CR11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s11904-015-0273-9","volume":"12","author":"AR Eckard","year":"2015","unstructured":"Eckard AR, McComsey GA. The role of statins in the setting of HIV infection. Curr HIV\/AIDS Rep. 2015;12(3):305\u201312.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"506_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/718329","volume":"2015","author":"E Ammirati","year":"2015","unstructured":"Ammirati E, Moroni F, Norata GD, Magnoni M, Camici PG. Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerosis. Med Inflamm. 2015;2015: 718329.","journal-title":"Med Inflamm"},{"issue":"2","key":"506_CR13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.hlc.2020.09.003","volume":"30","author":"AM Sethwala","year":"2021","unstructured":"Sethwala AM, Goh I, Amerena JV. Combating inflammation in cardiovascular disease. Heart Lung Circ. 2021;30(2):197\u2013206.","journal-title":"Heart Lung Circ"},{"issue":"1","key":"506_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/QCO.0000000000000223","volume":"29","author":"CT Longenecker","year":"2016","unstructured":"Longenecker CT, Eckard AR, McComsey GA. Statins to improve cardiovascular outcomes in treated HIV infection. Curr Opin Infect Dis. 2016;29(1):1\u20139.","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"506_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/0049825021000017957","volume":"33","author":"H Fujino","year":"2003","unstructured":"Fujino H, Yamada I, Shimada S, Yoneda M, Kojima J. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica. 2003;33(1):27\u201341.","journal-title":"Xenobiotica"},{"issue":"6","key":"506_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157531","volume":"11","author":"A Wongprikorn","year":"2016","unstructured":"Wongprikorn A, Sukasem C, Puangpetch A, Numthavej P, Thakkinstian A, Kiertiburanakul S. Effects of pitavastatin on lipid profiles in HIV-infected patients with dyslipidemia and receiving atazanavir\/ritonavir: a randomized, double-Blind, crossover study. PLoS One. 2016;11(6): e0157531.","journal-title":"PLoS One"},{"key":"506_CR17","unstructured":"The Heart Association of Thailand Uncer the Royal Patronage of H.M. the King. thai chronic coronary syndrome guidelines 2021. 2022. http:\/\/www.thaiheart.org\/images\/introc_1646981507\/Thai%20Chronic%20Coronary%20Syndromes%20Guidelines%202021.pdf. Accessed 3 Jan 2023."},{"key":"506_CR18","unstructured":"The Royal College of Physicians of Thailand. 2016 clinical practice guideline on pharmacologic therapy of dyslipidemia for atherosclerotic cardiovascular disease prevention 2017. http:\/\/www.thaiheart.org\/images\/column_1487762586\/2016%20RCPT%20Dyslipidemia%20Clinical%20Practice%20Guideline.pdf. Accessed 3 Jan 2023."},{"issue":"6","key":"506_CR19","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/QAD.0000000000001427","volume":"31","author":"M Toribio","year":"2017","unstructured":"Toribio M, Fitch KV, Sanchez L, Burdo TH, Williams KC, Sponseller CA, et al. Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV. AIDS. 2017;31(6):797\u2013806.","journal-title":"AIDS"},{"issue":"7","key":"506_CR20","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1016\/S2352-3018(17)30075-9","volume":"4","author":"JA Aberg","year":"2017","unstructured":"Aberg JA, Sponseller CA, Ward DJ, Kryzhanovski VA, Campbell SE, Thompson MA. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. Lancet HIV. 2017;4(7):e284\u201394.","journal-title":"Lancet HIV"},{"issue":"6","key":"506_CR21","doi-asserted-by":"publisher","first-page":"H1029","DOI":"10.1152\/ajpheart.00527.2015","volume":"309","author":"EM Domouzoglou","year":"2015","unstructured":"Domouzoglou EM, Naka KK, Vlahos AP, Papafaklis MI, Michalis LK, Tsatsoulis A, et al. Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21. Am J Physiol Heart Circ Physiol. 2015;309(6):H1029-38.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"13","key":"506_CR22","doi-asserted-by":"publisher","first-page":"7094","DOI":"10.1111\/jcmm.15296","volume":"24","author":"L Guo","year":"2020","unstructured":"Guo L, Liu MF, Huang JN, Li JM, Jiang J, Wang JA. Role of interleukin-15 in cardiovascular diseases. J Cell Mol Med. 2020;24(13):7094\u2013101.","journal-title":"J Cell Mol Med"},{"issue":"19","key":"506_CR23","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1161\/CIRCULATIONAHA.117.032615","volume":"137","author":"I Taguchi","year":"2018","unstructured":"Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): a randomized superiority trial. Circulation. 2018;137(19):1997\u20132009.","journal-title":"Circulation"},{"issue":"6","key":"506_CR24","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/infdis\/jiq115","volume":"203","author":"A Ganesan","year":"2011","unstructured":"Ganesan A, Crum-Cianflone N, Higgins J, Qin J, Rehm C, Metcalf J, et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis. 2011;203(6):756\u201364.","journal-title":"J Infect Dis"},{"issue":"1","key":"506_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/xJAHA.111.000125","volume":"1","author":"E Ammirati","year":"2012","unstructured":"Ammirati E, Cianflone D, Vecchio V, Banfi M, Vermi AC, De Metrio M, et al. Effector memory T cells are associated with atherosclerosis in humans and animal models. J Am Heart Assoc. 2012;1(1):27\u201341.","journal-title":"J Am Heart Assoc"},{"issue":"38","key":"506_CR26","doi-asserted-by":"publisher","first-page":"abd2712","DOI":"10.1126\/sciadv.abd2712","volume":"6","author":"N Patsoukis","year":"2020","unstructured":"Patsoukis N, Wang Q, Strauss L, Boussiotis VA. Revisiting the PD-1 pathway. Sci Adv. 2020;6(38):abd2712.","journal-title":"Sci Adv"},{"issue":"7109","key":"506_CR27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature05115","volume":"443","author":"CL Day","year":"2006","unstructured":"Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443(7109):350\u20134.","journal-title":"Nature"},{"issue":"8","key":"506_CR28","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486\u201399.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"506_CR29","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1038\/s41591-019-0590-4","volume":"25","author":"DM Fernandez","year":"2019","unstructured":"Fernandez DM, Rahman AH, Fernandez NF, Chudnovskiy A, Amir ED, Amadori L, et al. Single-cell immune landscape of human atherosclerotic plaques. Nat Med. 2019;25(10):1576\u201388.","journal-title":"Nat Med"},{"issue":"58","key":"506_CR30","doi-asserted-by":"publisher","first-page":"98215","DOI":"10.18632\/oncotarget.21003","volume":"8","author":"I Okoye","year":"2017","unstructured":"Okoye I, Namdar A, Xu L, Crux N, Elahi S. Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling. Oncotarget. 2017;8(58):98215\u201332.","journal-title":"Oncotarget"},{"key":"506_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ahj.2018.12.016","volume":"212","author":"SK Grinspoon","year":"2019","unstructured":"Grinspoon SK, Fitch KV, Overton ET, Fichtenbaum CJ, Zanni MV, Aberg JA, et al. Rationale and design of the randomized trial to prevent vascular events in HIV (REPRIEVE). Am Heart J. 2019;212:23\u201335.","journal-title":"Am Heart J"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-023-00506-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-023-00506-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-023-00506-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T09:05:22Z","timestamp":1677488722000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-023-00506-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["506"],"URL":"https:\/\/doi.org\/10.1186\/s12981-023-00506-2","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,27]]},"assertion":[{"value":"14 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Ethical Clearance Committee on Human Right Related to Research Involving Human Subjects of the Faculty of Medicine Ramathibodi Hospital, Mahidol University (MURA2014\/18).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}